Scientists at Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have identified high affinity nerve growth factor receptor (NTRK1; TrkA) inhibitors reported to be useful for the treatment of pain, cancer, inflammation and neurodegenerative diseases.

Onquality Pharmaceuticals China Ltd. has synthesized prodrugs of tofacitinib acting as JAK inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis and alopecia areata.

Baylor College of Medicine has disclosed proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to Bruton tyrosine kinase (BTK)-, DNA-binding protein Ikaros (IKZF1)- and Zinc finger protein Aiolos (IKZF3)-targeting moieties through a linker.

Aleksia Therapeutics Inc. has described CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

AC Immune SA has divulged compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of multiple system atrophy (MSA), Parkinson’s dementia, Lewy body dementia, Alzheimer’s disease and Parkinson’s disease, among others.

Scientists at Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have identified compounds reported to be useful for the treatment of cancer.

Korean Research Institute of Bioscience and Biotechnology has synthesized compounds reported to be useful for the treatment of non-tuberculous mycobacterial infections.

Chinese researchers have disclosed interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of psoriasis and more.

Frontier Medicines Corp. has described cellular tumor antigen p53 (TP53) (mutant) stabilizers reported to be useful for the treatment of cancer.

Mirati Therapeutics Inc. has divulged GTPase KRAS (G12S mutant) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.